$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma

The University of Oklahoma received a five-year, $2.9 million National Cancer Institute grant to study RedHill's investigational opaganib alongside CAR T-cell therapy in high-risk multiple myeloma. Planned trials include a Phase 1b study of up to 18 patients focused on safety and dosage, followed by a Phase 2 study of up to 21 additional patients seeking preliminary evidence of efficacy. The clinical benefit remains unproven; the trials are planned and will be conducted with RedHill and other partners.

Analysis

This is scientific validation, not a near-term earnings event for RedHill Biopharma (RDHL): the grant funds the university’s research program, while RDHL’s stated contribution is supplying investigational drug. The commercial value to RDHL depends on eventual clinical success, rights, and a viable development/commercialization path—none is established here. The small planned cohorts and long funding horizon make the result highly binary and unlikely to materially change near-term revenue or cash-generation absent a separate financing or partnership update.

The contrarian risk is treating preclinical promise and an NCI award as de-risking the asset. They support trial execution, not human efficacy; the mechanism may not translate, and CAR-T outcomes can be affected by multiple factors beyond persistence of T-cell activity. On-campus manufacturing could help OU’s trial logistics, but should not be extrapolated to lower costs or faster commercial CAR-T delivery elsewhere.

Near term, RDHL may receive a sentiment-driven pop; a fade is plausible if investors price the grant as company funding or a clinical milestone. Over 1–3 months, the useful checks are trial activation, enrollment, and any disclosed obligations or rights for RDHL. The structural read-through is years away and hinges first on safety/dose findings, then a credible efficacy signal. Failure to initiate or prolonged enrollment delays, dose-limiting toxicity, or no response signal would weaken the thesis. Hyloris Pharmaceuticals (HYL) has no apparent exposure to this program; Bayer AG’s separate opaganib study is not evidence for this CAR-T combination.

Key Decisions for Investors

• No fundamental trade on this announcement alone; do not treat the university grant as financing or revenue for RDHL. Avoid chasing a headline-driven move and reassess after the initial reaction.
• For existing RDHL exposure, treat the program as long-dated, high-risk optionality rather than a near-term catalyst. Track trial registration/activation, first-patient dosing, safety and dose selection, enrollment pace, and whether RDHL discloses any economic or development rights.
• Upgrade the signal only if human safety permits the planned combination and subsequent data show a credible efficacy signal; downgrade on material trial delay, dose-limiting toxicity, or failure to produce an interpretable response. Verify timing against the trial registry and company filings.
• No trade implied for HYL or BAYN from this announcement: neither has a stated role in the OU trial, and BAYN’s separate opaganib study should be evaluated on its own data.